Dermatology ·
iPLEDGE changes take effect for isotretinoin; bosakitug misses phase 2 atopic dermatitis goals, Aclaris says

Listen to this post
read by AI voices · all episodesTHE SHORT READ
Changes to the iPLEDGE program for isotretinoin took effect Nov. 15, allowing home monthly pregnancy tests and dropping monthly counseling documentation for patients who cannot become pregnant, according to the Food and Drug Administration (FDA).
Aclaris Therapeutics said bosakitug missed its primary and secondary end points in the phase 2 ADMIRATION trial in moderate to severe atopic dermatitis.
THE DETAILS
- FDA Nov 15, 2026Changes to the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) for isotretinoin took effect Nov. 15, according to the Food and Drug Administration (FDA). After initial in-office testing, patients who can become pregnant may take later monthly pregnancy tests outside a medical setting, including at home, and missing the seven-day pickup window no longer triggers an added waiting period. For patients who cannot become pregnant, monthly counseling documentation in the system and the 30-day prescription window were eliminated.Sources: FDA, Dermatology Times
- Research Nov 16, 2026Aclaris Therapeutics said Nov. 16 that bosakitug did not meet the primary end point, percentage change from baseline in Eczema Area and Severity Index score at week 24, or its secondary end points in the phase 2 ADMIRATION trial in moderate to severe atopic dermatitis, Dermatology Times reported. The company did not release numerical efficacy results or treatment-group comparisons in its topline announcement and has not announced further development plans for the drug.Source: Dermatology Times
The weekly innovation roundup for dermatology, published every Sunday for the week before; every item links to its sources. Latest dermatology news · All specialties